NCT04018118 Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
| NCT ID | NCT04018118 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Eosinophilia |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2019-05-06 |
| Primary Completion | 2029-05-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2019-05-06 with a primary completion date of 2029-05-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments. Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)
Eligibility Criteria
Inclusion Criteria: * Men or Women of any age : * With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO) * With an AEC \> 1500/mm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic) * HES diagnosis since 2005/01/01 * Patients socially insured * Patient who agreed to participate to the study, its proceedings and duration. Exclusion Criteria: * Known HIV infection * Not socially insured * Person unable to receive a enlighten information * Person who refuse to sign the consent * Persons deprived of their liberty * Persons benefiting from a system of legal protection (tutelage / guardianship)
Contact & Investigator
Guillaume Lefevre
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT04018118 clinical trial?
This trial is open to participants of all sexes, studying Eosinophilia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04018118 currently recruiting?
Yes, NCT04018118 is actively recruiting participants. Contact the research team at Guillaume.lefevre@chru-lille.fr for enrollment information.
Where is the NCT04018118 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT04018118 clinical trial?
NCT04018118 is sponsored by University Hospital, Lille. The principal investigator is Guillaume Lefevre at University Hospital, Lille. The trial plans to enroll 600 participants.